Medicare's 2027 Doctor Pay Cut Is a Relative-Price Reset: Plan Payments Rise 2.48% While Physician Fees Fall 2.31%

The arithmetic behind the headline is mechanical. A one-time 2.50% increase written into the 2026 schedule by the Working Families Tax Cut legislation does not repeat, so current law alone requires a 2.50% reduction before anything else; the statutory update adds 0.75% for qualifying APM participants and 0.25% for everyone else, and a 0.12% work-RVU adjustment takes a little more off. CMS also finished harder than it started: the non-APM cut deepened from 1.68% in the July proposal to 2.31% in the final rule. On the other side of the ledger, the April rate announcement hands Medicare Advantage plans 2.48% and more than $13 billion, and the hospital outpatient rules add 2.3%.

MedPAC read the same data differently. In its March 2026 report the commission recommended raising 2027 physician rates by 0.5 percentage points above current law, which after the 2.50% expiry still leaves a net decline of 1.2% for APM participants and 1.7% for other clinicians. Opens a 0.6-point gap between what CMS finalized and what the advisory panel says is adequate — and MedPAC priced the fix at $750 million to $2 billion in the first year and $1 billion to $5 billion over five.

Medicare's cost index and its fee schedule have been drifting apart for a quarter-century. Over 2000–2024 the Medicare Economic Index rose 56% while cumulative fee-schedule updates rose 14%, even as fee-schedule spending per fee-for-service beneficiary rose 104%. MedPAC projects index growth of 2.2% in 2026 and 2.1% in 2027, so the 2.31% cut to non-APM physicians lands below the cost trend CMS itself projects for 2027, while the 1.83% cut to APM participants still clears it. That is not a shock, but it is a wedge opening between what a physician earns per hour and what that hour costs.

CMS created no AI code in CY2027, and it did not need to. It opened payment for the outputs that automated and team-based care can produce while cutting the price of the physician visit that carries them. The final rule creates two advance care planning codes, establishes a national payment pathway for health and well-being coaching under general supervision, adds flexible time-based add-on codes for shared medical appointments, and boosts valuations for smoking cessation and behavioral health assessment. It also finalizes remote monitoring changes — remote therapeutic monitoring limited to established patients, a separately reportable initiating visit, updated valuations — and delays the practice-employed staffing requirement for remote monitoring to January 1, 2029.

Surgery Partners is the case study. Third-quarter revenue of $815.3 million was 0.8% below a year earlier even as same-facility revenue rose 6.0%; adjusted EBITDA slipped to $132.7 million from $136.4 million; net interest expense of $67.9 million consumed 51% of quarterly adjusted EBITDA; the company posted a $21.1 million net loss attributable to shareholders; total debt stood at $3,055.2 million and credit-agreement leverage was about 4.4 times. It then withdrew forward guidance because of a pending transaction and sold itself.

At $26.73 a share on November 10, 2026, Surgery Partners trades above the most the transaction can pay. That is the market's verdict on a 4.4-times-levered provider: the equity is now a deal, not a business. The same arithmetic decides who can still own physician cost. With reimbursement flat to down and the long end near 5%, the levers left are volume, labor cost and scale, and an operator carrying $3.1 billion of debt and $67.9 million of quarterly interest has none of them left. Turns a 2.31% price cut into a sale process — and hands the assets to a buyer with a lower cost of capital.

Read the scoreboard as a payment-architecture table, not a performance table. Fee-for-service exposure is punished, Medicare Advantage exposure is rewarded, and the spread between them is roughly 4.79 points in 2027 alone. That does not make every aligned company a winner — it sorts them by how much of their revenue sits on each side of the line.

Three things would break this thesis. Congress can restore the cut in December and hand fee-for-service physicians a flat-to-up 2027. Medicare Advantage can go the other way: the rate announcement is set once a year, and a plan year of worse-than-expected utilization can absorb a 2.48% increase without adding a cent to provider rates. And the productivity bet can fail — if AI-assisted documentation does not actually free up physician hours, the only remaining adjustment is volume, and volume is exactly what the access data says there is no room for. The clean test is whether primary care visits per physician rise in 2027 without appointment waits getting longer.

The investable conclusion is not that a 1.8% to 2.3% price change breaks the physician business; a program whose cost index has run 56% against 14% of cumulative updates absorbs such cuts for years. It is that CMS in 2026 chose to pay for care around the physician and less for the physician's own hour, while Medicare Advantage and hospital outpatient prices went up. Moves the margin pool from physician labor toward platforms, teams and whoever owns the patient's episode. The exposures that fit the mechanism are labor scarcity carried on a workable balance sheet, per-patient payment architecture with scale and cash, and — for the levered operators — a credit instrument rather than a growth story.